Immunate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

The human factor VIII component participates in the intrinsic pathway of the coagulation cascade, enabling conversion of factor X to Xa. The von Willebrand factor component promotes platelet adhesion to damaged vessels and stabilizes factor VIII, together restoring effective hemostasis.

The dose of Immunate is individualized. A qualified prescriber determines the amount and infusion rate based on the patient’s weight, severity of deficiency, and clinical response. No standard dosing regimen is provided here.

Safety data for Immunate in pregnancy and lactation are limited. Use is generally reserved for situations where the benefit to the mother outweighs potential risks to the fetus or infant, and decisions should be made by the treating physician.

To request Immunate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Immunate is a plasma‑derived product containing both factor VIII and von Willebrand factor, whereas some alternatives provide only recombinant factor VIII or only von Willebrand factor. The combined formulation can simplify therapy for patients with dual deficiencies, but individual product choice depends on clinical needs, inhibitor status, and physician preference.

Immunate must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the product. Follow any additional handling instructions provided with the shipment.

Immunate is given by intravenous infusion. The healthcare professional prepares the sterile solution according to the product label and administers it over the recommended infusion time, monitoring the patient for any adverse reactions during and after the infusion.

Serious risks include the development of neutralizing inhibitors against factor VIII, severe allergic reactions such as anaphylaxis, and thromboembolic events. Patients should be closely monitored for signs of these complications, and immediate medical attention is required if they occur.

Immunate is contraindicated in individuals with known hypersensitivity to any component of the product or to plasma‑derived clotting factors. It should also be used with caution in patients with a history of severe thrombosis or those who have previously developed inhibitors to factor VIII.